$PRTO News
Last published 6y ago
- 6y agoPRTONew patent application published for: Recombinant Elastase Proteins and Methods of Manufacturing and Use ThereofUS Patent Applications (USPTO)
- 6y agoTARAPRTOArTara Therapeutics Completes Merger Transaction with Proteon TherapeuticsGlobeNewswireShares of ArTara to commence trading on Nasdaq under new ticker symbol “TARA” effective January 10, 2020 Company completes previously announced equity financing of $42.5 million concurrently with the...
- 6y agoLPTPRTORARXCARTMoore Kuehn, PLLC Encourages Liberty Property Trust (LPT), Proteon Therapeutics (PRTO), Ra Pharmaceuticals (RARX), Carolina Trust BancShares (CART), and Highlands Bankshares (HLND) Investors to Contact FirmPR NewswireMoore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors...
- 6y agoVSIJAGPRTOROANMoore Kuehn, PLLC Encourages Vitamin Shoppe, Inc. (VSI), Jagged Peak Energy Inc. (JAG), Proteon Therapeutics, Inc. (PRTO), and Roan Resources, Inc. (ROAN) Investors to Contact FirmPR NewswireMoore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims involving the directors...
- 7y agoPRTOProteon Therapeutics Announces Third Quarter 2019 Financial ResultsGlobeNewswireWALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel,...
- 7y agoRYTMSNDXPRTOJDRF T1D Fund Appoints Veteran Life Sciences Executive Dr. Steven St. Peter as Managing DirectorBusiness WireBOSTON--(BUSINESS WIRE)--The JDRF T1D Fund, the venture philanthropy fund focused on accelerating life-changing solutions to cure, prevent, and treat type 1 diabetes (T1D) through catalytic investments, today announced the expansion of its investment team with the addition of Steven St. Peter, M.D., as a Managing Director. Based in Boston, Dr. St. Peter will work alongside Executive Chairman Sean ...
- 9y agoPRTOProteon Therapeutics' (PRTO) Management Discuses Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial Conference (Transcript)Earnings Call Transcripts